MarginsXMarginsX
Home › Markets › Health Care › PBLS

Parabilis Medicines Inc. (PBLS)

PBLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$28.45
+0.07% on the day
Market cap
$3.5B
Mid cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerPBLS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0001657677
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
43.1 months
$521.2M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$441.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$521.2M cash; operating cash flow -$36.3M a quarter.Report 2026-09-30
Shares outstanding125,257,825 (2026-11-09).Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-06-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $441.4M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.1M-$44.5M-$41.1M$521.2M$3.3MNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$148K-$52.5MNot filed$1.1B$11.4MNeeds four quarters10-Q 2026-08-13
Q3 2026
2026-03-31
Not filed-$45.3MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-09-30
$0-$33.5M-$31.5M$57.4MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2025-06-30
$0-$34.8MNot filed$80.4MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q3 2026
2025-03-31
Not filed-$38.3MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-06-10
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 65 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.4%
1 month+5.9%
3 months-20.3%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-31.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
OGNOrganon & Co. Common Stock$13.900.00%$3.7B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier